Hologic, Inc. (NASDAQ:HOLX) Shares Purchased by Trexquant Investment LP

Trexquant Investment LP lifted its position in Hologic, Inc. (NASDAQ:HOLX) by 36.1% in the 4th quarter, HoldingsChannel.com reports. The firm owned 235,152 shares of the medical equipment provider’s stock after acquiring an additional 62,337 shares during the quarter. Trexquant Investment LP’s holdings in Hologic were worth $16,802,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in HOLX. Corient Private Wealth LLC raised its position in Hologic by 251.1% during the fourth quarter. Corient Private Wealth LLC now owns 51,106 shares of the medical equipment provider’s stock worth $3,652,000 after acquiring an additional 36,550 shares during the period. D.A. Davidson & CO. acquired a new position in Hologic during the fourth quarter worth $204,000. Coldstream Capital Management Inc. acquired a new position in Hologic during the fourth quarter worth $305,000. Hillsdale Investment Management Inc. purchased a new stake in shares of Hologic during the fourth quarter worth $550,000. Finally, PNC Financial Services Group Inc. grew its holdings in shares of Hologic by 0.9% during the fourth quarter. PNC Financial Services Group Inc. now owns 31,933 shares of the medical equipment provider’s stock worth $2,282,000 after buying an additional 288 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on HOLX. William Blair reaffirmed an “outperform” rating on shares of Hologic in a report on Friday, February 2nd. JPMorgan Chase & Co. upped their target price on shares of Hologic from $85.00 to $91.00 and gave the stock an “overweight” rating in a report on Friday, May 3rd. StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. Evercore ISI upped their price objective on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a report on Thursday, April 4th. Finally, Citigroup raised shares of Hologic from a “neutral” rating to a “buy” rating and upped their price objective for the company from $80.00 to $95.00 in a report on Wednesday, April 3rd. Five equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $85.60.

Insider Transactions at Hologic

In other news, Director Charles J. Dockendorff sold 1,465 shares of the stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $76.21, for a total transaction of $111,647.65. Following the sale, the director now owns 1,572 shares of the company’s stock, valued at $119,802.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Charles J. Dockendorff sold 1,465 shares of the stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $76.21, for a total transaction of $111,647.65. Following the sale, the director now owns 1,572 shares of the company’s stock, valued at $119,802.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Scott T. Garrett sold 16,441 shares of the stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the sale, the director now directly owns 48,611 shares in the company, valued at approximately $3,670,130.50. The disclosure for this sale can be found here. Corporate insiders own 1.75% of the company’s stock.

Hologic Trading Down 0.2 %

NASDAQ HOLX traded down $0.17 during trading hours on Monday, reaching $74.85. The company had a trading volume of 1,007,176 shares, compared to its average volume of 1,707,998. The stock has a 50-day moving average of $76.25 and a 200 day moving average of $73.71. Hologic, Inc. has a 1-year low of $64.02 and a 1-year high of $82.45. The company has a current ratio of 3.97, a quick ratio of 3.29 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $17.47 billion, a P/E ratio of 38.18, a price-to-earnings-growth ratio of 2.50 and a beta of 1.01.

Hologic (NASDAQ:HOLX) last posted its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $0.98 by $0.05. Hologic had a net margin of 11.78% and a return on equity of 18.91%. The company had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1 billion. During the same quarter in the prior year, the company posted $1.06 earnings per share. Hologic’s revenue for the quarter was down .8% compared to the same quarter last year. As a group, research analysts anticipate that Hologic, Inc. will post 4.08 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.